ArticlePloS one2017
Physiological effects of a novel artificially synthesized antimalarial cyclic peptide: Mahafacyclin B.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mahafacyclin B is a cyclic peptide isolated from the latex of Jatropha mahafalensis and is an antimalarial agent. However, the physiological effects of mahafacyclin B in mammalian cells are not known. Here, we assessed the growth, morphology, and alterations in the transcriptome of CHO-K1 cells exposed to mahafacyclin B (0-22 μM). Mahafacyclin B at 2.2 μM did not affect the proliferation or death of CHO-K1 cells. Mahafacyclin B was not toxic to mammalian cells at 2.2 μM, which represents a normal physiological concentration at which mahafacyclin B retains its antimalarial properties. Interestingly, mahafacyclin B altered the size and morphology of CHO-K1 cells. Comparative transcriptomics revealed that mahafacyclin B modulated the expression of a specific subset of genes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.